Immundiagnostik AG
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
2
Ending by 2030
Apr 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 22, 2027The maintenance fee for Determination of vitamin D metabolites in dried blood (US 9,140,711) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients (US 10,613,101) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,579 | Osteogenic implant matrices and endosseous tooth implants with improved osteointegration properties In force · From the USPTO record | In force | From the USPTO record | |
| US 7,964,363 | Direct determination of vitamin D in serum or plasma In force · From the USPTO record | In force | From the USPTO record | |
| US 9,140,711 | Determination of vitamin D metabolites in dried blood In force · From the USPTO record | In force | From the USPTO record | |
| US 10,317,419 | Means and Methods of Measuring Parathyroid Hormone in Patients Suffering from Oxidative Stress In force · High confidence | In force | High confidence | |
| US 10,613,101 | Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients In force · From the USPTO record | In force | From the USPTO record | |
| US 9,823,258 | In vitro diagnostic and prognosis of major adverse events in patients undergoing coronary angiography In force · From the USPTO record | In force | From the USPTO record | |
| US 10,253,092 | Medicament and Apparatus for Treating Chronic Kidney Disease In force · High confidence | In force | High confidence | |
| US 10,947,301 | Method of treating extracellular tissue and vascular calcification and arteriosclerosis In force · From the USPTO record | In force | From the USPTO record | |
| US 11,221,337 | Method and test kit for the quantitative determination of biomarkers in fecal samples In force · From the USPTO record | In force | From the USPTO record | |
| US 11,085,922 | Method of measuring auto-antibodies in bodily fluids In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 14: 3 patents in force now held by others · 1 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 2 abandoned · 8 no status recorded